Servier
Also known as: ADIR, a Servier Group company | Biogaran | Institut de Recherches Internationales Servier | Institut de Recherches Internationales Servier (I.R.I.S.) | Les Laboratoires Servier (LLS) | Les Laboratoires Servier (L.L.S), Russia | Servier | SERVIER | Servier Affaires Médicales | Servier Bio-Innovation LLC | Servier Laboratories (Australia) Pty Ltd | Servier Pharmaceuticals LLC | Servier Pharmaceuticals, LLC | SERVIER PHARMA LLC
Highest phase reached
Phase 4
First clinical trial
Nov 1, 2000First marketed drug
Feb 1, 1994First NDA
Dec 20, 2018Last known activity
Mar 31, 2026
Timeline
1950s
- Jan 1, 1954
Servier— Founded
2010s
- Jul 20, 2018
ivosidenib— Marketing Organization
- Jul 20, 2018
ivosidenib— NDA Secondary Org
- Dec 20, 2018
calaspargase pegol— NDA Organization
2020s
- Apr 7, 2020
Symphogen A/S— Acquired
- Dec 21, 2020
Agios Pharmaceuticals, Inc.— Acquired
Drugs by trial phase (130 distinct, 199 trials)
Phase 4 (11 own, 1 via acquisition)
Phase 3 (27 own, 9 via acquisition)
Phase 2 (28 own, 13 via acquisition)
Phase 1 (21 own, 20 via acquisition)
Indications
Studied for
- Alzheimer Disease
- Angina Pectoris
- Angina, Stable
- Atrial Fibrillation
- Autism Spectrum Disorder
- Autistic Disorder
- Behcet Syndrome
- Breast Neoplasms
- Carcinoma
- Carcinoma, Neuroendocrine
- Cardiovascular Diseases
- Child Development Disorders, Pervasive
- Cholangiocarcinoma
- Cognitive Dysfunction
- Colorectal Neoplasms
- Compulsive Personality Disorder
- Coronary Artery Disease
- Coronary Disease
- Depression
- Depressive Disorder
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Disease
- Essential Hypertension
- Heart Failure
- Hypercholesterolemia
- Hypertension
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Liver Diseases
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Non-Hodgkin
- Major Depressive Disorder
- Melanoma
- Multiple Myeloma
- Multiple Organ Failure
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Myelodysplastic Syndromes
- Myocardial Ischemia
- Neoplasms
- Neoplasms, Plasma Cell
- Obsessive-Compulsive Disorder
- Osteoarthritis
- Osteoarthritis, Knee
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Proctitis
- Psychotic Disorders
- Rectal Neoplasms
- Recurrence
- Schizophrenia
- Schizophrenia, Paranoid
- Sclerosis
- Sjogren's Syndrome
- Syndrome
- Triple Negative Breast Neoplasms
- Uveal Neoplasms
- Uveitis
- Vascular Diseases
- Venous Insufficiency
- Ventricular Dysfunction
- Ventricular Dysfunction, Left
Marketed drugs (5)
Subsidiaries (2 direct, 2 total across the full acquisition tree)
Recent trials (50)
- NCT05592743CollaboratorN/A—
- NCT05592743Study directorN/A—
- NCT05592743Lead sponsorN/A—
- NCT07250633Lead sponsorPhase 1Mar 31, 2026
- NCT07286292Lead sponsorPhase 2Mar 15, 2026
- NCT07227857Lead sponsorPhase 1/Phase 2Nov 30, 2025
- NCT07260175CollaboratorPhase 2Nov 18, 2025
- NCT07235774Lead sponsorPhase 1Nov 5, 2025
- NCT07235748Lead sponsorPhase 1Oct 7, 2025
- NCT07006688CollaboratorPhase 1Sep 30, 2025
- NCT07006688Lead sponsorPhase 1Sep 30, 2025
- NCT07071844CollaboratorPhase 2Sep 30, 2025
- NCT07028424CollaboratorPhase 2Jul 31, 2025
- NCT05312372CollaboratorPhase 1/Phase 2May 31, 2025
- NCT05312372Lead sponsorPhase 1/Phase 2May 31, 2025
Details
- Founded
- Suresnes, FR Jan 1, 1954
- First NDA
- Dec 20, 2018
- Last known activity
- Mar 31, 2026
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy